A survey on lower urinary tract symptoms (LUTS) among patients with benign prostatic hyperplasia (BPH) in hospital universiti sains malaysia (HUSM) (original) (raw)
Related papers
The Journal of Urology, 1997
Purpose: We investigated the international differences in the reporting of lower urinary tract symptoms and related bother in patients with symptoms suggestive of bladder outlet obstruction. Materials and Methods: Multiple logistic regression analysis was used to evaluate interna tional differences in the reporting of lower urinary tract symptoms and related bother in 1,271 patients from 12 countries who participated in the International Continence Society "benign prostatic hyperplasia" study. Results: Country of origin was significantly associated with the prevalence of a large number of lower urinary tract symptoms (10 of 20), even after adjusting for potentially confounding variables, including physical and socio-demographic factors. Country of origin was also signifi cantly associated with the reporting of bother but for a much smaller number of symptoms (2). Conclusions: In different countries lower urinary tract symptoms may be reported to different extents. Therefore, the results of studies in particular countries may not be generally applicable to other countries. It is likely that symptom scores will conceal this variation, necessitating consid eration of individual symptoms (as in the International Continence Society "benign prostatic hyper plasia" study) or the development of country specific scoring systems. An alternative would be to focus on bother, which appeared to be much less sensitive to international differences.
Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors
Current Bladder Dysfunction Reports, 2010
The epidemiology of benign prostatic hyperplasia (BPH) and male lower urinary tract symptoms (LUTS) has evolved considerably during the past several years. The term LUTS describes a distinct phenotype and allows for a broad epidemiologic description of urinary symptoms at a population level. Although it is becoming the preferred term for studying urinary symptoms in populations, LUTS remains interconnected with
The Canadian journal of urology, 2011
Significant lower urinary tract symptoms (LUTS) are very common in men over age 50. It is appropriate for the primary care physician to perform the work up to confirm that benign prostatic hyperplasia (BPH) is causing the LUTS. If the physician determines that the patient has moderate symptoms (an International Prostate Symptom Score [IPSS] ≥ 8), moderate 'bother' (≥ 3 on the IPSS "bothersome index" question), and an enlarged (> 30 cc) prostate, then the most effective treatment is combination therapy with an alpha blocker and 5-alpha reductase inhibitor (5-ARI) at the time of confirmed BPH diagnosis. This combination will provide the most dramatic, early symptom response, the most sustained symptom response, and the most durable, reliable prevention of long term sequelae (acute urinary retention or the need for surgery), if the patient is compliant with taking the combination therapy.
The Canadian journal of urology, 2014
In the primary care office the evaluation of prostate related lower urinary tract symptoms (BPH-LUTS) in the male can be confusing. Are the symptoms, in fact, from the prostate or is there another etiology such as the bladder or medical conditions causing or contributing to the problems? If the cause is the prostate, how does the physician choose from the multitude of available treatment options and when is referral appropriate? The prevalence of BPH-LUTS is high and commonly encountered by the primary care physician (PCP). An understanding of the normal prostate is essential to identifying the patient when symptoms do occur. Then the evaluation and treatment of the affected patient can occur effectively and efficiently in the PCP setting. In this article we present the background information needed for the PCP to provide this evaluation of the patient with BPH-LUTS. We explain the various treatment options that are best suited for the individual which are based on symptom severity,...
Federal Practitioner, 2021
• FEDERAL PRACTITIONER • 573 mdedge.com/fedprac Background: Benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) are common clinical encounters for most primary care practitioners (PCPs). More than 50% of men aged > 50 years will develop significant lower urinary tract symptoms. Managing these symptoms can be complicated and requires an informed discussion between the PCP and the patient. This article provides a comprehensive review for PCPs regarding the evaluation and management of LUTS in men and when to consider a urology referral. Observations: Over the past 3 decades, medications have become the most common BPH and LUTS therapy, but recently, newer minimally invasive surgeries have challenged this paradigm. PCPs are in a unique position to help many patients who present with early stage LUTS. Conclusions: A clear understanding of the available treatment options will help PCPs counsel patients appropriately about lifestyle modification, medications, and surgical treatment options for their symptoms.
Indonesian Journal of Urology
Objective: This study aims to determine the relationship between Lower Urinary Tract Symptoms (LUTS) in patients with Benign Prostatic Hyperplasia (BPH) and erectile dysfunction at Raden Mattaher Hospital Jambi. Material & Methods: This research is an observational analytic with a cross sectional approach. The sample of this study includes 48 people using total sampling technique. Data analysis was carried out to test the hypothesis by the Spearman correlation test. Results: Based on the results of the Spearman correlation test analysis showed that there was a statistically significant relation (p=0.000) between Lower Urinary Tract Symptoms (LUTS) in patients with Benign Prostatic Hyperplasia (BPH) and erectile dysfunction. Conclusion: There is a significant relation between Lower Urinary Tract Symptoms (LUTS) in patients with Benign Prostatic Hyperplasia (BPH) and erectile dysfunction at Raden Mattaher Hospital Jambi.